Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-742457 monotherapy dose-ranging study in mild to moderate Alzheimer's disease
2005-000979-18Phase 2Completed
- Sponsor
- GSK
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of intepirdine in Alzheimer's disease (AD) (4 arms), sponsored by GSK. Primary endpoints: Cognitive function at 24 weeks and Global functioning at 24 weeks. Started May 2005; status: completed.
02
Drugs
intepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2005-000979-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000979-18.